Digital monitoring of disease activity in relapsing-remitting multiple sclerosis [0.03%]
复发缓解型多发性硬化症的数字化监测疾病活动度
P C G Molenaar,D J de Jong,S N Hof et al.
P C G Molenaar et al.
Background: Digital monitoring shows promise for detecting disease activity in people with relapsing-remitting multiple sclerosis (PwRRMS). Here, we study associations between digital biomarkers for cognition and walking ...
Balance biomarker for early differentiation of Parkinson's disease and multiple system atrophy with parkinsonian type [0.03%]
帕金森病和具帕金森症状的多系统萎缩早期鉴别平衡生物标志物
Hee Jin Chang,Jong Ho Kim,Han-Wook Song et al.
Hee Jin Chang et al.
Background: Parkinson's disease (PD) and multiple system atrophy with parkinsonian type (MSA-P) share various motor and nonmotor symptoms, complicating early differential diagnosis, although prognosis and levodopa respons...
Myasthenia gravis and pregnancy: a systematic review and meta-analysis [0.03%]
重症肌无力和妊娠：系统性回顾及meta分析研究
Lisa Miegel,Julia Hickstein,Antonia Reibelt et al.
Lisa Miegel et al.
Background: Myasthenia gravis (MG) is an autoimmune disease with an onset age distribution in women, which peaks within the reproductive age range, leading to a potential interference with pregnancy. In this systematic re...
Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS [0.03%]
抑郁和焦虑症状是进行性多发性硬化症多领域残疾进展的早期预测因素
Romy A M Klein Kranenbarg,Katelijn M Blok,Yifan van Hasselt et al.
Romy A M Klein Kranenbarg et al.
Introduction: In multiple sclerosis (MS), depression and anxiety are common, yet their relation to disease progression is unclear. We investigated whether Hospital Anxiety and Depression Scale (HADS) symptoms predict neur...
Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer's disease [0.03%]
血浆p-tau217检测有效预测淀粉样蛋白状态但缺乏阿尔茨海默病tau分期的精确性
Yuhan Chen,Zhibo Wang,Huan Chen et al.
Yuhan Chen et al.
Blood-based biomarkers for Alzheimer's disease (AD) have demonstrated high performance in identifying amyloid-β (Aβ) pathology. However, the diagnostic accuracy of commercial plasma biomarker assays in predicting PET-defined AD stages-par...
Intellectual disability and structural defects of the CaV2.1 channel in episodic ataxia type 2: correlation using an AI prediction model [0.03%]
人工智能预测模型在反复性阵发性共济失调2型中的智力障碍和CaV2.1通道结构缺陷的相关性研究
Hyo-Jung Kim,Jin-Ok Lee,Sejoon Lee et al.
Hyo-Jung Kim et al.
Background: Episodic ataxia type 2 (EA2) results from pathogenic variants in CACNA1A that encodes the CaV2.1 P/Q-type calcium channel. The molecular basis of cognitive impairments requires further elucidation in EA2. ...
Andrew J Larner,Alex P Leff
Andrew J Larner
Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy [0.03%]
一项开放性、多剂量II期试验的结果：在7至小于18岁的杜氏肌营养不良症男孩中研究vamorolone(VBP15-006)
Hanns Lochmüller,Hernan Gonorazky,Elisa Nigro et al.
Hanns Lochmüller et al.
Background: Vamorolone is a dissociative glucocorticoid receptor agonist for treating Duchenne muscular dystrophy (DMD). The VBP15-006 study assessed vamorolone safety, tolerability, and pharmacokinetics in 2- to < 4 and ...
Clinical Trial
Journal of neurology. 2026 Mar 3;273(3):177. DOI:10.1007/s00415-026-13711-6 2026
Non-sensorimotor symptoms in chronic inflammatory demyelinating polyneuropathy [0.03%]
慢性炎症性脱髓鞘多发神经病的非感觉运动症状
Fabian Klostermann,Oliver L Steiner
Fabian Klostermann
Chronic inflammatory demyelinating polyneuropathy (CIDP) is defined as a dysimmune disorder of the peripheral nervous system (PNS) resulting in sensorimotor deficits. However, an increasing body of data suggests that CIDP also goes along wi...
Claire Rice,Neil Scolding
Claire Rice
Primary CNS vasculitis (PCNSV) is uncommon, difficult to diagnose, and potentially fatal or at least likely to cause major and persistent neurological deficits, and yet appears highly treatable (although controlled clinical trials remain to...